Literature DB >> 22799590

Fundamentals of population pharmacokinetic modelling: validation methods.

Catherine M T Sherwin1, Tony K L Kiang, Michael G Spigarelli, Mary H H Ensom.   

Abstract

Population pharmacokinetic modelling is widely used within the field of clinical pharmacology as it helps to define the sources and correlates of pharmacokinetic variability in target patient populations and their impact upon drug disposition; and population pharmacokinetic modelling provides an estimation of drug pharmacokinetic parameters. This method's defined outcome aims to understand how participants in population pharmacokinetic studies are representative of the population as opposed to the healthy volunteers or highly selected patients in traditional pharmacokinetic studies. This review focuses on the fundamentals of population pharmacokinetic modelling and how the results are evaluated and validated. This review defines the common aspects of population pharmacokinetic modelling through a discussion of the literature describing the techniques and placing them in the appropriate context. The concept of validation, as applied to population pharmacokinetic models, is explored focusing on the lack of consensus regarding both terminology and the concept of validation itself. Population pharmacokinetic modelling is a powerful approach where pharmacokinetic variability can be identified in a target patient population receiving a pharmacological agent. Given the lack of consensus on the best approaches in model building and validation, sound fundamentals are required to ensure the selected methodology is suitable for the particular data type and/or patient population. There is a need to further standardize and establish the best approaches in modelling so that any model created can be systematically evaluated and the results relied upon.

Entities:  

Mesh:

Year:  2012        PMID: 22799590     DOI: 10.1007/BF03261932

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  55 in total

1.  The pharmacokinetics of methanol in the presence of ethanol: a case study.

Authors:  Carolyn V Coulter; Geoffrey K Isbister; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2011-04       Impact factor: 6.447

2.  Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.

Authors:  Wai Johnn Sam; Lai San Tham; Michael J Holmes; Marion Aw; Seng Hock Quak; Kang Hoe Lee; Seng Gee Lim; Krishnan Prabhakaran; Sui Yung Chan; Paul C Ho
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

4.  Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data.

Authors:  B Frame; J Koup; R Miller; R Lalonde
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children.

Authors:  Elke H J Krekels; Joost DeJongh; Richard A van Lingen; Caroline D van der Marel; Imti Choonara; Anne M Lynn; Meindert Danhof; Dick Tibboel; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2011-01       Impact factor: 6.447

6.  Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Authors:  Gezim Lahu; Andreas Hünnemeyer; Edgar Diletti; Martin Elmlinger; Peter Ruth; Karl Zech; Nigel McCracken; Axel Facius
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

7.  Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

Authors:  Wolfgang Mueck; Anthonie W A Lensing; Giancarlo Agnelli; Hervé Decousus; Paolo Prandoni; Frank Misselwitz
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

8.  Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.

Authors:  Flora T Musuamba; Annick Rousseau; Jean-Louis Bosmans; Jean-Jacques Senessael; Jean Cumps; Pierre Marquet; Pierre Wallemacq; Roger K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.

Authors:  Mahesh N Samtani; An Vermeulen; Kim Stuyckens
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.

Authors:  Pål Falck; Karsten Midtvedt; Thanh Trúc Vân Lê; Live Storehagen; Hallvard Holdaas; Anders Hartmann; Anders Asberg
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more
  27 in total

1.  Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections.

Authors:  Sylvain Goutelle; Sandrine Roux; Marie-Claude Gagnieu; Florent Valour; Sébastien Lustig; Florence Ader; Frédéric Laurent; Christian Chidiac; Tristan Ferry
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

2.  Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease.

Authors:  Adam Frymoyer; Daniël R Hoekman; Travis L Piester; Tim G de Meij; Thalia Z Hummel; Marc A Benninga; Angelika Kindermann; K T Park
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-12       Impact factor: 2.839

3.  Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery.

Authors:  Sara L Van Driest; Matthew D Marshall; Brian Hachey; Cole Beck; Kim Crum; Jill Owen; Andrew H Smith; Prince J Kannankeril; Alison Woodworth; Richard M Caprioli; Leena Choi
Journal:  Br J Clin Pharmacol       Date:  2016-04-15       Impact factor: 4.335

4.  Population Pharmacokinetics of Mycophenolic Acid: An Update.

Authors:  Tony K L Kiang; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

5.  Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.

Authors:  Yan Rong; Patrick Mayo; Mary H H Ensom; Tony K L Kiang
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

6.  Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.

Authors:  Sarah E Lacher; Julia N Gremaud; Kasse Skagen; Emily Steed; Rachel Dalton; Kent D Sugden; Fernando Cardozo-Pelaez; Catherine M T Sherwin; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2013-12-02       Impact factor: 4.030

7.  External Validation of a Recently Developed Population Pharmacokinetic Model for Hydromorphone During Postoperative Pain Therapy.

Authors:  Harald Ihmsen; Doris Rohde; Jürgen Schüttler; Christian Jeleazcov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 8.  Voriconazole: A Review of Population Pharmacokinetic Analyses.

Authors:  Changcheng Shi; Yubo Xiao; Yong Mao; Jing Wu; Nengming Lin
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

9.  Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.

Authors:  Celeste Bloomfield; Christine E Staatz; Sean Unwin; Stefanie Hennig
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Prediction of paraquat exposure and toxicity in clinically ill poisoned patients: a model based approach.

Authors:  Klintean Wunnapuk; Fahim Mohammed; Indika Gawarammana; Xin Liu; Roger K Verbeeck; Nicholas A Buckley; Michael S Roberts; Flora T Musuamba
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.